Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2020
The collaboration will research and develop an extended delivery formulation of aflibercept via the suprachoroidal space.